Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to add SNV4818, a mutant‑selective PI3Kα inhibitor, to its oncology pipeline. Novartis said SNV4818 aims to selectively inhibit tumor‑mutant PI3Kα while sparing wild‑type enzyme, a design intended to reduce tolerability issues that limit earlier PI3Kα inhibitors. The deal accelerates Novartis’ strategy to target PIK3CA‑mutated HR+/HER2‑ breast cancer and to enable earlier‑line combinations with hormonal agents. Pikavation’s program is in Phase I/II testing and has shown preclinical selectivity and activity across common PIK3CA mutations. Novartis framed the acquisition as precision‑medicine extension that could improve combination tolerability and dosing consistency versus older non‑selective PI3Kα agents, a company executive said in the announcement.